Cencora raises 2026 profit forecast and buyback plan
U.S. drug distributor Cencora increased the lower end of its fiscal 2026 adjusted earnings forecast to a range of $17.70 to $17.90 per share following recent stock repurchases. The company also authorized a new $2 billion share buyback program to follow its existing $1 billion plan.
Xurve View
Insights:
Xurve View
CENCORA INC raised the lower end of its fiscal 2026 earnings forecast to $17.70–$17.90 per share and authorized a $2 billion share buyback. The revision follows the completion of $1 billion in stock repurchases in May. The company earlier this month cut its revenue growth forecast on slower U.S. sales while raising its annual adjusted profit forecast to $17.65–$17.90 per share from $17.45–$17.75 per share.
